Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-12-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the number of patients with advanced, relapsed
non-small cell lung cancer who can tolerate dose escalation sorafenib from 400 mg twice daily
to either 600 mg twice daily or 800 mg twice daily. Safety and tolerability of sorafenib will
also be examined.